Detalhe da pesquisa
1.
Ex Vivo Fluorescence Confocal Microscopy (FCM) Ensures Representative Tissue in Prostate Cancer Biobanking: A Feasibility Study.
Int J Mol Sci
; 23(20)2022 Oct 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36292970
2.
Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial.
World J Urol
; 39(1): 65-72, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-32189088
3.
Ex Vivo Fluorescence Confocal Microscopy of MRI-Guided Targeted Prostate Biopsies for Rapid Detection of Clinically Significant Carcinomas-A Feasibility Study.
Cancers (Basel)
; 16(5)2024 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38473235
4.
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
J Cancer Res Clin Oncol
; 147(1): 235-242, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-32886212
5.
Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
J Cancer Res Clin Oncol
; 147(1): 243-244, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-33346877
6.
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten's to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial).
J Cancer Res Clin Oncol
; 147(4): 1273-1274, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33625578